Spyre Therapeutics Inc. (SYRE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.44B
Last updated: Nov 17, 2026 at 4:15 PM ET
Spyre Therapeutics Inc. (SYRE) Statistics
Spyre Therapeutics (SYRE) has a market cap of $9.44B and an enterprise value of $9.35B. It kept -291.57% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 0.88% below the market cap, as cash exceeds debt.
| Market Cap | $9.44B |
|---|---|
| Enterprise Value | $9.35B |
| Latest price (Nov 17, 2026) | $93.81 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 299.19% over 52 weeks and trades 2.25% above its 50-day average.
| Beta (1Y) | 1.70 |
|---|---|
| 52-Week Change | +299.19% |
| 1-Month Change | +10.73% |
| 3-Month Change | -13.87% |
| 6-Month Change | +40.81% |
| 5-Year Change | -47.23% |
| 10-Year Change | -27.94% |
| Total Return (1Y) | +299.19% |
| Total Return (3Y CAGR) | +109.14% |
| Total Return (5Y CAGR) | -10.55% |
| Return vs SPY (1Y) | +277.69% |
| Max Drawdown (1Y) | -27.81% |
| Max Drawdown (3Y) | -73.99% |
| Sharpe Ratio (1Y) | 2.08 |
| Correlation with SPY (1Y) | 0.36 |
| 50-Day Average | $91.75 |
| 200-Day Average | $77.31 |
| 52-Week Range | $23.01 to $110.64 |
| RSI (14 Days) | 46.2 |
| Average Volume (20 Days) | 943.54K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 27.40x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 27.40x |
|---|---|
| Quick Ratio | 27.40x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -25.09% over the last 12 months, against a 5-year average of -98.20%.
| Return on Equity (ROE) | -25.09% |
|---|---|
| Return on Assets (ROA) | -23.99% |
| ROE (5Y Average) | -98.20% |
| ROA (5Y Average) | -66.18% |
| ROIC (5Y Average) | -25.18% |
| Asset Turnover | 0.11x |
Scores
SYRE has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $90.49M over the last 12 months.
| Revenue | $90.49M |
|---|---|
| Gross Profit | $45.25M |
| Operating Income | -$250.17M |
| Pretax Income | -$263.86M |
| Net Income | -$263.86M |
| Reported EPS (TTM) | -$2.78 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.45% of the $1.10B in total assets.
| Cash and Equivalents | $82.73M |
|---|---|
| Total Debt | $0 |
| Net Cash | $82.73M |
| Working Capital | $1.06B |
| Shareholder Equity | $1.05B |
| Total Assets | $1.10B |
| Total Liabilities | $48.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$249.32M |
|---|---|
| FCF Per Share | -$2.67 |
| Depreciation and Amortization | $11.58M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -276.45%.
| Gross Margin | 50.00% |
|---|---|
| Operating Margin | -276.45% |
| Pretax Margin | -291.57% |
| Net Margin | -291.57% |
Stock Splits
The last split was a 1-for-25 reverse split on Sep 8, 2023.
| Last Split Date | Sep 8, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SYRE
What is SYRE's market cap?
Spyre Therapeutics has a market cap of $9.44B. Its enterprise value, which adds debt and subtracts cash, is $9.35B.
Does SYRE pay a dividend?
No. Spyre Therapeutics does not pay a dividend.
How much debt does SYRE have?
Spyre Therapeutics has $0 of total debt and $82.73M of cash and equivalents, a net cash position of $82.73M.
SYRE pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors